Ulka Vaishampayan, MD | Authors


Cabozantinib Plus Nivolumab Improves Efficacy Over Sunitinib in mRCC

October 31, 2020

Ulka Vaishampayan, MD, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib plus nivolumab as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.